In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

Pathology oncology research: POR

article

Shibuya, Isao¹  Takami, Masamichi³  Miyamoto, Arei¹  Karakawa, Akiko³  Dezawa, Akira²  Nakamura, Shigeru²  Kamijo, Ryutaro¹ 

[1] Department of Biochemistry, Showa University School of Dentistry;Department of Orthopaedic Surgery, Teikyo University Mizonokuchi Hospital;Department of Pharmacology, Showa University School of Dentistry

关键词: Giant cell tumor of bone;    Osteoclast;    Bisphosphonate;    Denosumab;    Bone tumor;   

DOI  :  10.1007/s12253-017-0362-8

来源: Springer

【 摘 要 】

Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that contains numerous osteoclasts formed from marrow-derived precursors through receptor activator of nuclear factor κ-B ligand (RANKL), an osteoclast differentiation factor expressed in neoplastic cells of GCTB. Denosumab, a fully human monoclonal antibody targeting RANKL, has recently been used for the treatment of GCTB, and superior treatment effects have been reported. The aim of this work was to elucidate the mechanism of action of denosumab, and the differences between denosumab and zoledronic acid at the level of GCTB cells. We isolated GCTB cells from 3 patients and separated them into osteoclasts, osteoclast precursors and proliferating spindle-shaped stromal cells (the true neoplastic component), and examined the action of denosumab on differentiation, survival and bone resorption activity of osteoclasts. Denosumab and zoledronic acid inhibited osteoclast differentiation from mononuclear cells containing osteoclast precursors. Zoledronic acid inhibited osteoclast survival, whereas an inhibitory effect of denosumab on osteoclast survival was not observed. The inhibitory effect on bone resorption by both agents was confirmed in culture on dentin slices. Furthermore, zoledronic acid showed dose-dependent inhibition of cell growth of neoplastic cells whereas denosumab had no inhibitory effect on these cells. Denosumab has an inhibitory effect on osteoclast differentiation, but no inhibitory effects on survival of osteoclasts or growth of neoplastic cells in GCTBs.

【 授权许可】

Unknown